Dataset Information

Proteomic analysis of myoglobin deficient adipose tissue

ABSTRACT: This dataset contains mass spectrometry-based proteomics data from subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and brown adipose tissue (BAT) isolated from wild-type and adipose-tissue-specific myoglobin knockout (ATMBKO) mice maintained at room temperature (23°C), thermoneutrality (30°C), or exposed to cold (8°C). The objective of the study was to determine the contribution of adipose myoglobin to thermogenesis and thermoregulation. The dataset provides a resource to investigate depot-specific and temperature-dependent proteomic changes associated with adipose myoglobin deficiency.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Adipose Tissue

SUBMITTER: Kristin Schubert

LAB HEAD: Kristin Schubert

PROVIDER: PXD076825 | Pride | 2026-07-01

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20251016_ACMB15_BAT_1.raw	Raw
	20251016_ACMB15_BAT_1.raw.quant	Raw
	20251016_ACMB15_BAT_2.raw	Raw
	20251016_ACMB15_BAT_2.raw.quant	Raw
	20251016_ACMB15_BAT_3.raw	Raw

Items per page:

1 - 5 of 201

Publications

Adipocyte Myoglobin Is a Determinant of Energy Expenditure and a Potential Target to Limit Obesity.

Strehlau Christian C Broghammer Helen H Gebhardt Claudia C Hoffmann Anne A Hagemann Tobias T Midilli Şeyma Ş Zimmer Rachel S RS Schubert Kristin K Karagiannakou Vasiliki V Georgiadi Anastasia A Ost Mario M Krüger Martin M Roth Lisa L Krause Kerstin K Klöting Nora N Keller Maria M Wabitsch Martin M Nuwayhid Rima R Stimson Roland H RH Stumvoll Michael M Blüher Matthias M Weiner Juliane J Heiker John T JT

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20260625

Nutritional overflow and a positive energy balance are hallmarks of metabolic diseases including obesity and type 2 diabetes. Brown and beige adipocytes maintain systemic metabolic homeostasis by clearing and oxidizing energy-rich nutrients during thermogenic activation. Myoglobin (MB) is classically regarded as a muscle-associated oxygen-binding protein; however it is also expressed in brown and beige adipocytes, where it contributes to intracellular lipid handling and oxidative metabolism. Her ...[more]

PMID: 42348442

Similar Datasets

Project description:Acute pancreatitis (AP), a severe inflammatory disorder of the pancreas, lacks effective pharmacological treatment. The disease is primarily driven by necrosis of pancreatic acinar cells (PACs), which intensifies inflammation and organ injury. This study explores the potential of BCL2 inhibitors, specifically Navitoclax and Venetoclax, to shift cell death pathways from necrosis to apoptosis and thereby mitigate disease severity. Ex vivo models using cerulein or ethanol/palmitoleic acid (EtOH/POA) showed that both inhibitors significantly reduced necrosis, increased apoptosis, and improved PAC viability and ATP levels. In mouse models of AP, both drugs promoted apoptosis and decreased tissue necrosis, with Venetoclax showing superior efficacy and safety. Venetoclax markedly reduced disease severity in two AP models without affecting healthy tissue or inducing thrombocytopenia. In contrast, Navitoclax caused apoptosis even in healthy tissue and triggered thrombocytopenia. Importantly, both drugs attenuated pathological Ca2+ responses in PACs and upregulated the expression of Ca²⁺-binding proteins S100A8/A9 and the chemokine CCL8. The latter may mediate enhanced apoptotic clearance and limit secondary necrosis, supporting the therapeutic shift from necrosis to apoptosis. Proteomic analyses revealed extensive drug-induced remodeling. In the short-term AP model, both inhibitors altered expression of proteins linked to intracellular compartments and extracellular signaling, reflecting cellular adaptation. In CP, Navitoclax strongly upregulated ECM and lysosomal proteins while downregulating ribosomal components – indicating intensified fibrosis and suppressed protein synthesis. Venetoclax had milder effects and did not worsen fibrosis. Despite Navitoclax’s efficacy toward activated pancreatic stellate cells in vitro, it exacerbated fibrosis and tissue atrophy in CP in vivo, likely due to ongoing parenchymal damage and stellate cell activation. Together, these findings demonstrate that selective BCL2 inhibition with Venetoclax promotes apoptosis, reduces necrosis, and improves outcomes in AP, supporting its repurposing as a therapeutic strategy. However, BCL2 inhibition does not benefit CP and may aggravate fibrosis, underscoring the need for context-specific approaches.